Gall Matthew
Insider CIK 1816194 · KLRS Chief Financial Officer · ITOS Chief Financial Officer · TNGX Chief Financial Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics, Inc. | A Award deriv | 2026-05-01 | 2026-05-05 | 240,000 | — | $0 | 240,000 | SEC↗ |
| TNGX Tango Therapeutics, Inc. | A Award | 2026-05-01 | 2026-05-05 | 40,000 | — | $0 | 40,000 | SEC↗ |
| KLRS Kalaris Therapeutics, Inc. | A Award deriv | 2026-03-19 | 2026-03-20 | 95,000 | — | $0 | 95,000 | SEC↗ |
| KLRS Kalaris Therapeutics, Inc. | A Award deriv | 2025-11-03 | 2025-11-03 | 235,000 | — | $0 | 235,000 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | D To issuer deriv | 2025-08-29 | 2025-08-29 | 135,937 | — | $0 | 0 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | D To issuer deriv | 2025-08-29 | 2025-08-29 | 42,388 | — | $0 | 0 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | D To issuer deriv | 2025-08-29 | 2025-08-29 | 8,123 | — | $0 | 0 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | D To issuer deriv | 2025-08-29 | 2025-08-29 | 252,135 | — | $0 | 0 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | D To issuer deriv | 2025-08-29 | 2025-08-29 | 9,063 | — | $0 | 0 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | U Tender | 2025-08-29 | 2025-08-29 | 89,429 | — | $0 | 0 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | A Award deriv | 2025-03-07 | 2025-03-11 | 145,000 | — | $0 | 145,000 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | A Award | 2025-03-07 | 2025-03-11 | 24,000 | — | $0 | 89,429 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | P Buy | 2024-11-19 | 2024-11-19 | 5,000 | $7.73 | $38.6K | 65,429 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | A Award deriv | 2024-03-07 | 2024-03-08 | 163,200 | — | $0 | 163,200 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | A Award | 2023-12-05 | 2023-12-07 | 41,000 | — | $0 | 60,429 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | P Buy | 2023-10-12 | 2023-10-12 | 5,000 | $8.37 | $41.8K | 19,429 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | A Award deriv | 2023-03-09 | 2023-03-10 | 130,000 | — | $0 | 130,000 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | A Award deriv | 2022-03-11 | 2022-03-14 | 85,000 | — | $0 | 85,000 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | S Sale | 2021-12-27 | 2021-12-28 | 5,000 | $46.45 | $232.3K | 14,429 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | M Exercise deriv | 2021-10-11 | 2021-10-12 | 14,429 | — | $0 | 42,388 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | M Exercise | 2021-10-11 | 2021-10-12 | 14,429 | $6.16 | $88.9K | 19,429 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | A Award deriv | 2021-06-24 | 2021-06-25 | 24,000 | — | $0 | 24,000 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | P Buy | 2021-06-16 | 2021-06-16 | 5,000 | $26.09 | $130.4K | 5,000 | SEC↗ |
| ITOS iTeos Therapeutics, Inc. | A Award deriv | 2021-03-01 | 2021-03-03 | 72,000 | — | $0 | 72,000 | SEC↗ |